Systemic administration of enamel matrix derivative to lipopolysaccharide- challenged pigs: Effects on the inflammatory response

Surgical Infections

Volumn 9, Issue 2, 2008, Pages 161-169

  Gundersen, R Yngvar ^a,b   Ruud, Tom E ^a,c   Jørgensen, Pal F ^a   Scholz, Tim ^a   Reinholt, Finn P ^d   Wang, Jacob E ^a,e   Lyngstadaas, Stale P ^d   Aasen, Ansgar O ^a,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN DEFENCE RESEARCH ESTABLISHMENT FFI   (Norway)

^c VESTRE VIKEN HOSPITAL TRUST   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ENAMEL MATRIX DERIVATIVE; HEMOGLOBIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENAMEL; HEMODYNAMICS; INFLAMMATION; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DENTAL ENAMEL PROTEINS; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; SUS SCROFA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42449156686     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2007.007     Document Type: Article

References (29)

1. Gestrelius S, Andersson C, Lidström D, et al. In vitro studies of periodontal ligament cells and enamel matrix derivative. J Clin Periodontol 1997;24:685-692.
2. Gestrelius S, Lyngstadaas SP, Hammarström L. Emdogain: Periodontal regeneration based on biomimicry. Clin Oral Invest 2000;4:120-125.
3. Hammarström L, Heijl L, Gestrelius S. Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. J Clin Periodontol 1997;24:669-677.
4. Somerman MR, Sullivan HC. A clinical and histological evaluation of autogenous iliac bone grafts in human I: Wound healing 2 to 8 months. J Periodontol 1973;44:599-613.
5. Francetti L, del Fabbro M, Basso M, et al. Enamel matrix proteins in the treatment of intra-bony defects: A prospective 24-month clinical trial. J Clin Periodontol 2004;31:52-59.
6. Trieger N. An oral surgeon's evaluation of Emdogain. N Y State Dent J 2003;69:31-33.
7. Peteinaki E, Nikolopoulos S, Castanas E. Low stimulation of peripheral lymphocytes following in vitro application of Emdogain. J Clin Periodontol 1998;25:715-720.
8. Myhre AE, Lyngstadaas SP, Dahle MK, et al. Anti-inflammatory properties of enamel matrix derivative in human blood. J Periodont Res 2006;41:208-213.
9. Hurley JC. Endotoxemia: Methods of detection and clinical correlates. Clin Microbiol Rev 1995;8:268-292.
10. Ghosh S, Latimer RD, Gray BM, et al. Endotoxin-induced organ injury. Crit Care Med 1993;21:S19-S24.
11. Prueckner S, Safar P, Kentner R, et al. Mild hypothermia increases survival from severe pressure-controlled hemorrhage in rats. J Trauma 2001;50:253-262.
12. Ritter C, Andrades ME, Reinke A, et al. Treatment with N-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis. Crit Care Med 2004;32:342-349.
13. Grotz MRW, Pape H-C, van Griensven M, et al. Glycine reduces the inflammatory response and organ damage in a two-hit sepsis model in rats. Shock 2001;16:116-121.
14. Jørgensen PF, Götzinger P, Scholz T, et al. The role of Kupffer cell inhibition in porcine endotoxemia. Shock 2001;16:466-472.
15. Mirastschijski U, Konrad D, Lundberg E, et al. Effects of topical enamel matrix derivative on skin wound healing. Wound Repair Regen 2004;12:100-108.
16. Gundersen Y, Sëtre T, Scholz T, et al. Selective inhibition of inducible nitric oxide synthase maintains haemodynamic stability without untoward consequences for hepatic function or morphology. Eur J Surg 1999;165:1167-1174.
17. + regulatory T cells control innate immunity after injury. J Immunol 2005;174:2957-2963.
18. Nikolopoulos S, Peteinaki E, Castanas E. Immunologic effects of emdogain in humans: One-year result. Int J Periodont Restorative Dent 2002;22:269-277.
19. Giannobile WV, Somerman MJ. Growth and amelogenin-like factors in periodontal wound healing: A systematic review. Ann Periodontol 2003;8:193-204.
20. Szebeni J, Fontana JL, Wassef NM, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs. Circulation 1999;99:2302-2309.
21. Hakim RM, Breillatt J, Lazarus JM, Port FK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 1984;311:878-882.
22. Szebeni J, Baranyl L, Savay S et al. Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol 2000;279:H1319-H1328.
23. Fincham AG, Moradian-Oldak J, Simmer JP, et al. Self-assembly of a recombinant amelogenin protein generates supramolecular structures. J Struct Biol 1994;112:103-109.
24. Moradian-Oldak J, Leung W, Fincham AG. Temperature and pH-dependent supramolecular self-assembly of amelogenin molecules: A dynamic light-scattering analysis. J Struct Biol 1998;122:320-327.
25. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147.
26. Termine JD, Belcourt AB, Christner PJ, et al. Properties of dissociatively extracted fetal tooth matrix proteins I: Principal molecular species in developing bovine enamel. J Biol Chem 1980;255:9760-9768.
27. Veis A. Amelogenin gene splice products: Potential signaling molecules. Cell Mol Life Sci 2003;60:38-55.
28. Kawase T, Okuda K, Momose M, et al. Enamel matrix derivative (Emdogain™) rapidly stimulates phosphorylation of the MAP kinase family and nuclear accumulation of smad2 in both oral epithelial and fibroblastic human cells. J Periodont Res 2001;36:367-376.
29. 2 mediates lung vasoconstriction but not permeability after endotoxin. J Clin Invest 1983;72:911-918.